<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392613</url>
  </required_header>
  <id_info>
    <org_study_id>2003B118</org_study_id>
    <nct_id>NCT00392613</nct_id>
  </id_info>
  <brief_title>RAte Control Efficacy in Permanent Atrial Fibrillation</brief_title>
  <official_title>RAte Control Efficacy in Permanent Atrial Fibrillation, a Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <brief_summary>
    <textblock>
      The investigators hypothesis is that in patients with permanent AF lenient rate control is&#xD;
      not inferior to strict rate control in terms of cardiovascular mortality, morbidity,&#xD;
      neurohormonal activation, NYHA class for heart failure, left ventricular function, left&#xD;
      atrial size, quality of life and costs. Lenient rate control is defined as a resting heart&#xD;
      rate &lt;110 bpm.Strict rate control is defined as a mean resting heart rate &lt; 80 beats per&#xD;
      minute (bpm) and heart rate during minor exercise &lt; 110 bpm. Patients will be seen after 1,&#xD;
      2, 3 months (for titration of rate control drugs) and thereafter yearly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objectives:&#xD;
&#xD;
        1. To show that lenient rate control is not inferior to strict rate control in terms of&#xD;
           cardiovascular mortality and morbidity&#xD;
&#xD;
        2. To show that lenient rate control is not inferior to strict rate control in terms of all&#xD;
           cause mortality, cardiovascular hospitalizations, NYHA class for exercise tolerance,&#xD;
           left ventricular function and left atrial size, quality of life, neurohormonal&#xD;
           activation as measured by NT-proBNP, hospitalization for heart failure, syncope,&#xD;
           sustained ventricular tachycardia, appropriate shocks or anti-tachycardia pacing of ICD&#xD;
           for ventricular arrhythmias, cardiac arrest, and pacemaker implantations, stroke,&#xD;
           systemic emboli, and bleeding, unstable angina pectoris and myocardial infarction, costs&#xD;
           and renal function&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular mortality</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Syncope</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular tachycardia</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PM / ICD implantation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac arrest</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Life-threatening adverse effects of RC drugs</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospitalizations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV function and left atrial size</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Strict versus lenient rate control</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a current episode of permanent AF &lt; 12 months.&#xD;
&#xD;
          -  Age &lt;/= 80 years.&#xD;
&#xD;
          -  Mean resting heart rate &gt; 80 beats per minute with or without rate control medication&#xD;
&#xD;
          -  Oral anticoagulation (or aspirin if no risk factors for thromboembolic complications&#xD;
             are present).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal AF&#xD;
&#xD;
          -  Known contra-indications for either strict or lenient rate control (e.g. previous&#xD;
             adverse effects on negative chronotropic drugs).&#xD;
&#xD;
          -  Unstable heart failure defined as NYHA IV heart failure and heart failure&#xD;
             necessitating hospital admission &lt; 3 months before inclusion.&#xD;
&#xD;
          -  Cardiac surgery &lt; 3 months.&#xD;
&#xD;
          -  Any stroke.&#xD;
&#xD;
          -  Current or foreseen pacemaker and/ or cardiac resynchronization therapy.&#xD;
&#xD;
          -  Signs of sick sinus syndrome or AV conduction disturbances (i.e. symptomatic&#xD;
             bradycardia or asystole &gt; 3 seconds or escape rate &lt; 40 beats per minute in awake&#xD;
             symptom-free patients).&#xD;
&#xD;
          -  Untreated hyperthyroidism or &lt; 3 months euthyroidism.&#xD;
&#xD;
          -  Inability to walk or bike.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle C Van Gelder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>January 6, 2010</last_update_submitted>
  <last_update_submitted_qc>January 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

